Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.
World journal of urology. 2018 Nov 12 [Epub ahead of print]
Damiano Fantini, Joshua J Meeks
Department of Urology, Feinberg School of Medicine, Chicago, IL, USA., Department of Urology, Feinberg School of Medicine, Chicago, IL, USA. .